With all hands on deck for lead sick­le cell tri­al, Beam pulls back clin­i­cal plans for sec­ond base edit­ing ther­a­py

Al­most a year af­ter the FDA cleared their sick­le cell dis­ease pro­gram for a first-in-hu­man tri­al, the base edit­ing ex­perts at Beam Ther­a­peu­tics are still work­ing on en­rolling their first pa­tient.

As ex­ecs fo­cus on that mile­stone, a sec­ond ther­a­py for sick­le cell dis­ease will have to wait.

Beam an­nounced in its Q3 up­date that it’s push­ing back plans to file an IND in 2022 for BEAM-102, which takes an al­ter­na­tive ap­proach to treat the ge­net­ic blood dis­or­der.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER